MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 32.1% in March

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the recipient of a large decline in short interest in March. As of March 13th, there was short interest totaling 332,123 shares, a decline of 32.1% from the February 26th total of 489,206 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average trading volume of 169,231 shares, the short-interest ratio is presently 2.0 days.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on MIRA shares. Rodman & Renshaw began coverage on shares of MIRA Pharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a report on Friday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, MIRA Pharmaceuticals currently has a consensus rating of “Hold”.

Institutional Investors Weigh In On MIRA Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in shares of MIRA Pharmaceuticals by 100.0% in the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after buying an additional 136,438 shares in the last quarter. Fifth Third Bancorp bought a new stake in MIRA Pharmaceuticals during the fourth quarter worth $30,000. First American Bank raised its position in MIRA Pharmaceuticals by 20.0% during the fourth quarter. First American Bank now owns 60,000 shares of the company’s stock worth $91,000 after acquiring an additional 10,000 shares in the last quarter. Two Sigma Investments LP lifted its stake in MIRA Pharmaceuticals by 129.8% in the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after acquiring an additional 25,816 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in MIRA Pharmaceuticals in the second quarter valued at $26,000. Institutional investors and hedge funds own 35.16% of the company’s stock.

MIRA Pharmaceuticals Stock Performance

MIRA traded down $0.07 on Monday, hitting $0.96. 75,099 shares of the company were exchanged, compared to its average volume of 188,683. The stock’s fifty day moving average is $1.21 and its 200-day moving average is $1.36. MIRA Pharmaceuticals has a 12 month low of $0.73 and a 12 month high of $2.45. The company has a market cap of $40.34 million, a PE ratio of -0.63 and a beta of 1.78.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.